Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat diabetes, could help trim their ...

For more than 55 years, Institutional Investor has delivered the news and analysis that investment professionals need to succeed and stay relevant. Our coverage of the global asset management industry ...

The White House unveiled agreements with pharma giants Eli Lilly and Company and Novo Nordisk to offer GLP-1's Zepbound, orforglipron, Ozempic and Wegovy through the prescription digital marketplace ...

The Momentum score in Benzinga’s Edge Stock Rankings is calculated based on the relative strength of a stock, taking into consideration the price movements and volatility across multiple time frames, ...

Since tanking in early August, shares of Eli Lilly and Company (NYSE: LLY) have roared back with a vengeance. The world’s most valuable healthcare stock plummeted around 14% on Aug. 7 after releasing ...

Clara Stack's Lilly Bainbridge is one of the most tragic characters in the IT lore, as the first episode establishes that she spent some time in the Juniper Hill Asylum. The episode slowly reveals the ...

Eli Lilly's GLP-1 drug portfolio should power the business for at least the next decade. But the market appears well aware of the company's weight loss drug success. Weight loss drugs are set to ...

Eli Lilly's GLP-1 drug portfolio should power the business for at least the next decade. But the market appears well aware of the company's weight loss drug success. Weight loss drugs are set to ...

Eli Lilly is going for gold at the Milano Cortina 2026 Olympic and Paralympic Winter Games. In a pair of recent announcements, the Big Pharma was named an official sponsor of the Games, while also ...

Eli Lilly's GLP-1 drug portfolio should power the business for at least the next decade. But the market appears well aware of the company's weight loss drug success. Weight loss drugs are set to ...

Shares of Eli Lilly surged in early Thursday trading, as the drugmaker reported huge demand for its GLP-1 weight-loss and diabetes drugs, leading to record revenue and a raised full-year outlook. The ...